Trial
NCT04162470
REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Paroxysmal Nocturnal Hemoglobinuria
Intervention
REGN3918
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-12